Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims:
Soy (a vegetable foodstuff) contains chemicals called phyto-oestrogens (isoflavones) that have been shown to be of potential benefit to people during menopause as soy can alleviate menopausal hot flushes. It has also been shown that bones lose their density more rapidly during the immediate years following menopause. It is not really known if soy can have an effect on chemicals in the blood that reflects bone loss and growth. Therefore it is important to compare the effect of soy proteins, with and without phyto-oestrogens, on the bone health of women during this time.
This study aims to look at the effects of eating snack bars containing soy protein, with or without phyto-oestrogens, during the first two years of menopause. This will be done in such a way that neither the individual taking part, nor the investigator will know which type of bars the person has been eating.

Who can participate?
Women who have experienced menopause within the last 2 years

What does the study involve?
Participants will be asked to visit the research department a total of four times over a period of 6 months. They will also be contacted by telephone twice within this 6 month period. The first visit, that will last about 30 minutes, will involve discussing the study and signing a consent form. The subsequent visits will last around an hour.
1. At the second, third and final visit the participants will be asked to attend the clinic first thing in the morning, having fasted overnight. The blood samples will be tested for hormone levels and bone turn over makers.
2. At the second, third and final visit the participants will have an ultrasound scan examination of the lining of your womb.
3. At the second visit the participants will be given enough soy snack bars to eat twice a day (mid morning and mid afternoon) for 3 months.

What are the possible benefits and risks of participating?
Although there may be some direct benefits to some people taking part in the study, these will not be known until the study has finished. It is hoped that this study will help to provide the information needed to inform the Food Standards Agency and UK governments regarding the safety and potential benefits of eating soy and phytooestrogens to women during menopause.

Where is the study run from?
The University of Hull at Brocklehurst Building of Hull Royal Infirmary.

When is study starting and how long is it expected to run for?
The study started in July 2010 and will end in December 2012

Who is funding the study?
Food Standard Agency, UK

Who is the main contact?
Prof Stephen Atkin

Trial website

Contact information



Primary contact

Prof Stephen Atkin


Contact details

Hull York Medical School
Michael White Centre for Diabetes
Endocrinology & Metabolism
Brocklehurst Building
Hull Royal Infirmary
Anlaby Road
United Kingdom
+44 (0)1482 675312

Additional identifiers

EudraCT number number

Protocol/serial number

Protocol Version 2 date: 24/02/2012

Study information

Scientific title

A double blind placebo controlled parallel trial of soy isoflavones on markers of bone turnover in females in the early menopause


Study hypothesis

Null hypothesis:
Neither soy protein alone (15g without isoflavones) or soy protein (15g) with isoflavones (66mg) will have an effect on either bone resorption or bone formation (i.e. bone turnover) in post menopausal women at the time of their greatest bone loss.

Ethics approval

Yorkshire & The Humber - Humber Bridge Research Ethics Committee, 18/06/2010, ref: 10/H1304/5

Study design

Parallel double-blind placebo-controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Effect of soy phyto-eastrogens to people during menopause as soy have been shown to improve menopausal flusing symptoms.


A bar containing 7.5g isolated soy protein powder (Solcon F) with 33mg of isoflavones (given twice daily) or 7.5g of the isolated soy (extracted, isoflavone free) protein alone (given twice daily) as control will be administered.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Change in bone turnover markers

Secondary outcome measures

1. Insulin resistance
2. Blood pressure
3. Lipid profile
4. Endothelial function
5. Changes in endometrial thickness

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Women with a follicle-stimulating hormone (FSH) and luteinizing hormone (LH) greater than 20 mU/L and amenorrhoea for 1 year with or without vasomotor instability of hot flushing will be eligible to participate
2. Caucasian women

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Patients with liver dysfunction (ALT of greater than 135 u/L) or taking drugs that may interfere with liver function
2. Patients with impaired renal function (creatinine greater than 150, glomerular filtration rate less than 30)
3. Patients who have had antibiotic treatment within the last 6 months will also be ineligible for the study as antibiotics are known to change gut microflora and thus will interfere with phytoestrogen metabolism. This will also mean that patients who start taking antibiotics during the study will have to be withdrawn
4. Patients not wishing to allow disclosure to their GPs
5. Patients on any medication within 3 months of the study including steroid inhalers or HRT
6. Patients already self-supplementing with isoflavones
7. Vegetarian or vegans

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Hull York Medical School
United Kingdom

Sponsor information


Hull and East Yorkshire Hospitals NHS Trust (UK)

Sponsor details

Research and Development Department
Daisy Building
Castle Hill Hospital
Castle Road
HU16 5JQ
United Kingdom
+44 (0)1482 461903

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Food Standard Agency (UK), ref: T10060

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

1. 2018 results in:
2. 2018 results relating to thyroid hormone effects in

Publication citations

Additional files

Editorial Notes

17/12/2018: Publication reference added. 10/05/2018: Publication reference added. 17/10/2016: No publications found in PubMed, verifying study status with principal investigator. 13/12/2013: The overall trial start date was changed from 21/07/2010 to 29/09/2012 and the overall trial end date was changed from 30/12/2012 to 12/12/2013.